Patient-Focused Drug Design – A View from the R&D Front Lines

Incorporation of patient-focused drug design principles is increasingly becoming essential to ensure that a new drug is commercially successful and delivers the best patient outcomes. Often, patient factors and insights are not considered or discovered until the later phases of drug development when dose form, dose strength, and route of administration are already decided. There is tremendous potential benefit of equipping formulators and other scientists with patient insights earlier in the development process so that the drug product can be designed to address the specific needs of target patient populations.
Watch Now

Spotlight

OTHER ON-DEMAND WEBINARS

Studies of Mosquito Immunology and Plasmodium Virulence Using Imaging Flow Cytometry

Millipore Sigma

The classification of mosquito blood cells is controversial, complicated by the small size and number of cells one can obtain per mosquito, by the autofluorescent debris found in hemolymph, and the tendency of phagocytes to take up this autofluorescent debris. Much of the classification has been performed morphologically on cytospins of isolated cells. Imaging flow cytometry yields simultaneously acquired bright field, scatter, and fluorescent images of cells in suspension, enabling better resolution of rare cells from debris.
Watch Now

Best Process Best result Best Product Using Minitab for Superior Quality in the Pharmaceutical Industry.

minitab

Pharmaceutical manufacturers often have the task of reducing waste to meet company expectations, document the process to meet regulatory requirements and improve quality to meet customer specifications. Let's be honest, not achieving any of the above points is not an option in most pharmaceutical companies. That's where the capacity analysis comes into play.
Watch Now

COUNTERFEITING AND PHARMACEUTICAL PRODUCTS I.

The aim of this webinar is to promote the fight against IP Crime in the area of Counterfeiting and Pharmaceutical Products.
Watch Now

The 2nd Life Sciences Sector Deal and the NHS 10 Year Plan

pharmaphorum

Brexit uncertainty isn’t going away any time soon – but it’s important to remember that the UK government has already set out two plans for the future shape of the country’s healthcare industry: the second Life Sciences Sector Deal and the long-term plan for the NHS. With these two plans in place there are plenty of opportunities for the industry and the government to work together to keep the UK at the top of the international life sciences sector – and perhaps reach even greater heights.
Watch Now

Spotlight

resources